Back
Compare AU
Compare IMLC vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the IML Concentrated Aus Share Fund - Active ETF (IMLC) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IMLC | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 67 |
Median incremental investment | $997.50 | $738.73 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $2,182.32 | $1,958.52 |
Average age group | 26 - 35 | > 35 |
Key Summary
IMLC | DRUG | |
|---|---|---|
Strategy | IMLC.AX was created on 2023-08-01 by IML. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the S&P/ASX 300 Accumulation Index (after fees and expenses and before taxes) on a rolling four-year basis. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | CSL Ltd (10.36 %) The Lottery Corp Ltd (8.48 %) Brambles Ltd (8.40 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.993 % | 0.57 % |
Key Summary
IMLC | DRUG | |
|---|---|---|
Issuer | IML | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.993 % | 0.57 % |
Price | $4.33 | $8.56 |
Size | N/A | $168.713 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.35 % | 1.97 % |
Market | ASX | ASX |
First listed date | 31/07/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IMLC | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 67 |
Median incremental investment | $997.50 | $738.73 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $2,182.32 | $1,958.52 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
IMLC | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IMLC | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |